Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
Veklury save search
FDA Approves Veklury® (Remdesivir) to Treat COVID-19 in People With Mild to Severe Hepatic Impairment With no Dose Adjustment
Published: 2023-08-24 (Crawled : 18:00) - biospace.com/
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.27%
H: 1.15%
C: -1.19%
covid-19 veklury fda treat
FDA Approves Veklury® (Remdesivir) for COVID-19 Treatment in Patients With Severe Renal Impairment, Including Those on Dialysis
Published: 2023-07-14 (Crawled : 14:00) - biospace.com/
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: -0.13%
H: 1.34%
C: 0.76%
covid-19 veklury fda renal treatment dialysis
CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Severe Renal Impairment, Including Those on Dialysis
Published: 2023-05-26 (Crawled : 09:00) - biospace.com/
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.45%
H: 0.79%
C: -1.17%
covid-19 veklury chmp renal positive dialysis
CHMP Adopts Positive Opinion to Extend Indication of Veklury® (Remdesivir) for the Treatment of Pediatric Patients with COVID-19
Published: 2022-09-16 (Crawled : 11:00) - biospace.com/
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.12%
H: 1.31%
C: 0.8%
covid-19 veklury treatment chmp positive
Gilead Sciences Signs New Joint Procurement Agreement with the European Commission for Veklury® (Remdesivir)
Published: 2022-07-19 (Crawled : 13:20) - biospace.com/
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 1.24%
H: 1.0%
C: 0.75%
veklury sciences agreement
Veklury Skyrockets Gilead’s Q1 Earnings As Net Income Falls
Published: 2022-04-29 (Crawled : 16:00) - biospace.com/
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -0.13%
H: 0.0%
C: 0.0%
European Commission Expands Indication for Veklury (Remdesivir) for the Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease Progression
Published: 2021-12-21 (Crawled : 11:00) - biospace.com/
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.0%
H: 0.17%
C: -0.87%
covid-19 treatment europe risk oxygen covid disease
Gilead Sciences Announces Veklury® Donations to Help Address the Ongoing COVID-19 Crisis in Indonesia and Armenia
Published: 2021-10-19 (Crawled : 14:00) - biospace.com/
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.15%
H: 1.5%
C: 1.36%
covid ongoing
Veklury® (Remdesivir) Significantly Reduced Risk of Hospitalization in High-Risk Patients with COVID-19
Published: 2021-09-22 (Crawled : 14:00) - biospace.com/
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.47%
H: 0.15%
C: -0.96%
covid risk covid-19
Gilead’s Veklury® (Remdesivir) Associated With a Reduction in Mortality Rate in Hospitalized Patients With COVID-19 Across Three Analyses of Large Retrospective Real-World Data Sets
Published: 2021-06-21 (Crawled : 13:00) - biospace.com/
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.57%
H: 0.86%
C: 0.54%
covid
Genentech Provides Update on the Phase III REMDACTA Trial of Actemra Plus Veklury in Patients With Severe COVID-19 Pneumonia
Published: 2021-03-11 (Crawled : 09:00) - biospace.com/
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: -0.63%
H: 0.83%
C: -0.66%
covid trial
Roche provides update on the phase III REMDACTA trial of Actemra/RoActemra plus Veklury in patients with severe COVID-19 pneumonia
Published: 2021-03-11 (Crawled : 07:00) - globenewswire.com
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: -0.63%
H: 0.83%
C: -0.66%
covid ev trial
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.